Peptides for Obesity & Metabolic Disease
An educational hub on the peptide and incretin therapies reshaping the science of obesity and metabolic disease.
On This Page
About This Category
The medical category of 'obesity peptides' encompasses two overlapping families: the GLP-1 and dual/triple incretin-receptor agonists (semaglutide, tirzepatide, retatrutide), and the growth-hormone-axis peptides studied for visceral adiposity (tesamorelin, AOD-9604).
These compounds have shifted the medical understanding of obesity from a willpower problem to a neuro-endocrine condition — one with measurable, reproducible pharmacological levers in the central nervous system, the gut, and adipose tissue itself.
This hub is focused on the clinical and research framing: pathophysiology of obesity, the mechanisms by which incretin and GH-axis peptides exert their effects, the trial data behind the leading compounds, and how research-only peptides fit into a landscape increasingly dominated by FDA-approved agents.
History & Discovery
The modern era of obesity pharmacology began with the cloning of the GLP-1 gene in the 1980s and the recognition of GLP-1's incretin effect — a stronger insulin response to oral than intravenous glucose, mediated by gut peptides released in response to nutrient ingestion.
Exenatide, a synthetic version of exendin-4 from the Gila monster, became the first GLP-1 receptor agonist approved for type 2 diabetes in 2005 — the first member of the incretin therapeutic class. Liraglutide followed in 2010, expanding to obesity in 2014 as Saxenda.
Semaglutide (Ozempic 2017, Wegovy 2021) marked the inflection point. Once-weekly dosing combined with substantially greater weight loss than prior agents (~15% body weight at 68 weeks in the STEP trial program) reframed obesity as a treatable neuro-endocrine disease rather than a willpower problem.
Tirzepatide (Mounjaro 2022, Zepbound 2023) added GIP-receptor agonism to GLP-1 — the first dual agonist — and produced ~22% weight loss in the SURMOUNT trials. Retatrutide, currently in phase 3, adds glucagon-receptor activity for triple-agonist activity and ~24% weight loss in the phase 2 readout.
In parallel, tesamorelin's GH-axis approach to visceral fat established a separate pharmacological lever — selectively reducing the metabolically dangerous intra-abdominal depot rather than producing broad weight loss.
Mechanism of Action
Incretin-class peptides (GLP-1 receptor agonists and the newer dual/triple agonists) act centrally on hypothalamic appetite circuits — the arcuate nucleus, the paraventricular nucleus, and the area postrema — to reduce hunger and prolong satiety. Peripherally, they slow gastric emptying and improve glucose-dependent insulin secretion.
Tirzepatide adds GIP-receptor agonism, which appears to amplify weight loss beyond pure GLP-1 effects, possibly through GIP's role in adipose tissue metabolism and energy expenditure. Retatrutide adds glucagon-receptor activity, further increasing energy expenditure via hepatic and adipose mechanisms.
GH-axis peptides like tesamorelin act through a different pathway — restoring pulsatile growth hormone release, which preferentially mobilizes visceral (intra-abdominal) fat. This is the metabolically dangerous fat depot, and the one most resistant to caloric restriction alone.
AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone (residues 176–191), originally developed as a weight-loss agent. It retains the lipolytic effect of GH without the IGF-1 elevation, though clinical trial outcomes have been mixed.
Pharmacokinetics
| Semaglutide half-life | ~7 days (once-weekly dosing) |
| Tirzepatide half-life | ~5 days (once-weekly dosing) |
| Retatrutide half-life | ~6 days (once-weekly dosing, investigational) |
| Tesamorelin half-life | ~26 minutes (once-daily evening dosing) |
| AOD-9604 half-life | Estimated 30–60 minutes |
| Receptor mechanisms | GLP-1R · GIP-R · GCG-R · GHRH-R |
| Steady state (incretins) | Plateau by week 4–5 of weekly dosing |
Research Use Cases
Visceral Adipose Tissue Reduction
Tesamorelin remains the only FDA-approved agent specifically indicated for visceral fat reduction (in HIV-associated lipodystrophy). Studied for VAT reduction in non-HIV populations as well.
Type 2 Diabetes & Metabolic Syndrome
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed both diabetes care and obesity medicine. Trial data is among the deepest of any pharmacological category.
Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)
Hepatic fat reduction is a cross-cutting endpoint for both GLP-1 agonists and tesamorelin, with measurable improvements in liver fat fraction by MRI.
Cardiovascular Risk Reduction
The SELECT trial established cardiovascular benefit of semaglutide independent of diabetes status — a landmark in obesity-as-disease framing.
Inflammatory & Atherogenic Markers
GLP-1 agonists have demonstrated reductions in CRP, IL-6, and atherogenic lipid fractions — supporting the multi-system view of obesity pathology.
Behavioral & Reward-System Changes
Functional MRI studies show GLP-1 agonist effects on dopaminergic reward responses to food cues, suggesting CNS mechanisms beyond simple satiety.
Research Dosing Reference
Semaglutide (Wegovy) — FDA-approved obesity titration
Slow titration is the standard for managing GI side effects. Maintenance dose is 2.4 mg weekly.
Tirzepatide (Zepbound) — FDA-approved obesity titration
Maximum dose 15 mg/week. Maintenance can be at any tolerated step.
Tesamorelin (Egrifta SV) — clinical and research dosing
Selective for visceral fat. 26-week minimum to assess response.
Retatrutide — investigational research dosing
Phase 3 dosing schedule. Not FDA-approved.
AOD-9604 — research dosing
Modest effect-size in clinical trials; often paired with caloric deficit and resistance training in research designs.
Stacking & Combinations
Tirzepatide + Tesamorelin (preliminary research)
Tirzepatide drives broad weight loss; tesamorelin specifically targets visceral fat. Preliminary research is exploring whether the combination produces better metabolic outcomes than either alone — particularly in subjects with persistent VAT after substantial weight loss.
Semaglutide + Resistance Training
Not a pharmacological stack but the most important non-pharmacological pairing. Incretin-driven weight loss includes meaningful lean-mass loss; resistance training during weight loss preserves muscle and improves long-term outcomes.
GLP-1 Cycling Off Without Rebound
An emerging research area examining whether tapering off incretins while maintaining weight loss requires bridging strategies — caloric structure, behavioral support, or potentially other compounds (tesamorelin for visceral fat, GH-axis stacks for body composition).
Side Effect Profile
Common / Mild-to-Moderate
- •Nausea (most common with GLP-1 and dual/triple agonists, dose-related)
- •Vomiting and constipation
- •Diarrhea early in titration, often improving over weeks
- •Decreased appetite (the intended effect, occasionally distressingly so)
- •Fatigue, particularly in the first weeks of each dose escalation
- •Injection-site reactions
- •Tesamorelin-specific: peripheral edema, arthralgia, mild hyperglycemia
Serious / Less Common
- •Pancreatitis — uncommon but documented; warrants discontinuation if suspected
- •Gastroparesis exacerbation in predisposed subjects
- •Gallbladder disease (cholelithiasis) — increased incidence with substantial weight loss
- •Medullary thyroid carcinoma — black-box warning based on rodent studies; human relevance unclear
- •Severe hypoglycemia when combined with insulin or sulfonylureas
- •Tesamorelin-specific: hyperglycemia, retinopathy progression in diabetics
GI side effects are the dominant tolerability driver for incretin agents and the principal reason for the slow titration schedule. The serious-but-rare events listed above warrant clinical monitoring; routine bloodwork (lipase, A1c, lipid panel) is part of standard prescribing.
Storage & Reconstitution
- FDA-approved incretins (semaglutide, tirzepatide) are supplied as pre-filled pens or vials — no reconstitution required. Refrigerated at 2–8°C; can be kept at room temperature for limited periods per product labeling.
- Tesamorelin (Egrifta SV) is a lyophilized powder requiring reconstitution with bacteriostatic water; refrigerated post-reconstitution; ~14-day stability per label.
- Research-only compounds (AOD-9604, retatrutide research material) are typically lyophilized and require reconstitution with BAC water. Storage and reconstitution conventions follow standard peptide handling.
- Always rotate injection sites to avoid lipohypertrophy. Abdominal injection is standard for incretin-class agents; tesamorelin is also typically dosed abdominally.
- Refrigerate reconstituted material; allow to reach room temperature before injection to reduce sting.
Key Studies & Trial Data
STEP 1: Semaglutide for weight management in adults
Pivotal phase 3 trial. 1,961 adults with overweight or obesity randomized to semaglutide 2.4 mg weekly or placebo for 68 weeks. Treatment produced a 14.9% reduction in body weight versus 2.4% with placebo — the trial that established semaglutide as the new standard of obesity pharmacotherapy.
Wilding JPH, et al. NEJM. 2021;384(11):989–1002.
SURMOUNT-1: Tirzepatide for obesity
Pivotal phase 3 trial of tirzepatide. 2,539 adults randomized across three doses (5, 10, 15 mg weekly) versus placebo for 72 weeks. Maximum dose produced 22.5% weight reduction — the largest pharmacological weight loss in any obesity trial to date.
Jastreboff AM, et al. NEJM. 2022;387(3):205–216.
Retatrutide phase 2 weight loss
Triple GIP/GLP-1/glucagon agonist in 338 adults with obesity. The 12 mg arm produced 24.2% weight reduction at 48 weeks — the largest ever reported for any obesity drug, with a phase 3 program currently enrolling.
Jastreboff AM, et al. NEJM. 2023;389(6):514–526.
SELECT: Semaglutide cardiovascular outcomes
Cardiovascular outcomes trial in 17,604 adults with overweight/obesity and established CV disease, without diabetes. Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% — establishing CV benefit independent of glycemic effects and reframing obesity as a CV-modifiable disease.
Lincoff AM, et al. NEJM. 2023;389(24):2221–2232.
Comparisons & Deep Dives
In-depth articles on Peptide Basics that compare Peptides for Obesity & Metabolic Disease to related compounds and expand on its mechanism and use.
Best Peptides for Weight Loss
Side-by-side overview of the leading research compounds — semaglutide, tirzepatide, retatrutide, tesamorelin, AOD-9604.
How GLP-1 Works for Weight Loss
The neuroendocrine mechanism — central appetite circuits, gastric emptying, and the difference between glucose-dependent and constitutive insulin effects.
Why Semaglutide Doesn't Work for Some People
Non-response is a real clinical phenomenon. Genetic, behavioral, and pharmacokinetic explanations for the responder/non-responder split.
How Tesamorelin Works
Deep dive into the GHRH-receptor mechanism that drives selective visceral fat reduction.
Frequently Asked Questions
Where to Source Research-Grade Obesity Peptides
Base Peptide
Research-grade tesamorelin, AOD-9604, retatrutide, and related metabolic peptides with batch-specific Certificates of Analysis. The standard sourcing reference for non-prescription compounds in this category.
Other reputable suppliers known for batch-specific Certificates of Analysis:
Want a deeper, ongoing reference? Peptide Basics maintains a comprehensive resource on obesity peptides alongside calculators, reconstitution guides, and a database of 60+ research peptides.
Read more on Peptide Basics